Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vir Biotechnology Inc Market Cap
The Vir Biotechnology Inc (VIR) share price is expected to increase by 238.3% over the next year. This is based on calculating the average 12-month share price estimate provided by 9 stock analysts who have covered VIR. Price targets range from $10 at the low end to $110 at the high end. The current analyst consensus for VIR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Vir Biotechnology Inc has a total of 9 Wall St Analyst ratings. There are 6 buy ratings, 3 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vir Biotechnology Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VIR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Nov 20, 2024 |
| Joseph Stringer Needham | Buy | $19 | Reiterates | Nov 20, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Nov 4, 2024 |
| Gena Wang Barclays | Overweight | $26 | Maintains | Nov 4, 2024 |
| Joseph Stringer Needham | Buy | $19 | Reiterates | Nov 1, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Aug 20, 2024 |
| Gena Wang Barclays | Overweight | $28 | Maintains | Aug 2, 2024 |
| Michelle Gilson Morgan Stanley | Equal-Weight | $15 | Maintains | Jun 6, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Jun 5, 2024 |
| Joseph Stringer Needham | Buy | $19 | Maintains | Jun 5, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 24, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 7, 2024 |
| Eric Joseph JP Morgan | Neutral | $12 | Maintains | May 3, 2024 |
| Joseph Stringer Needham | Buy | $15 | Reiterates | May 3, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Mar 15, 2024 |
| Eric Joseph JP Morgan | Neutral | $10 | Maintains | Feb 23, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Maintains | Feb 14, 2024 |
| Eric Joseph JP Morgan | Neutral | $9 | Downgrade | Jan 29, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $85 | Maintains | Jan 23, 2024 |
| Joseph Stringer Needham | Buy | $15 | Maintains | Nov 3, 2023 |
When did it IPO
2019
Staff Count
587
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Market Cap
$1.20B
In 2023, VIR generated $39.5M in revenue, which was a decrease of -97.50% from the previous year. This can be seen as a signal that VIR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Janux Therapeutics shares surged following "unprecedented" results from an experimental prostate cancer treatment, indicating strong potential for the company's product.
Why It Matters - Janux Therapeutics' significant stock surge reflects strong investor confidence due to promising experimental results, potentially impacting future revenue and market position in cancer treatment.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology will host a virtual investor event on January 8, 2025, to discuss initial data on T-cell engagers targeting HER2 and PSMA, along with updates on the PRO-XTENâ„¢ platform.
Why It Matters - Vir Biotechnology's upcoming event on initial data for promising cancer treatments could impact stock performance and investor sentiment, indicating potential growth and innovation in the biotech sector.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology Inc. CEO Marianne De Backer will participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 3 at 6:10 a.m. PT. Webcast available on their website.
Why It Matters - Marianne De Backer's participation in the conference indicates potential updates on Vir Biotechnology's strategy and performance, influencing investor sentiment and stock movement.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology received a positive opinion from the EMA for orphan drug designation of tobevibart and elebsiran for chronic hepatitis delta, based on promising Phase 2 trial data.
Why It Matters - The positive opinion from the EMA for orphan drug designation can enhance Vir Biotechnology's market potential and attract investment, signaling promise in treating chronic hepatitis delta.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology announced positive results from its SOLSTICE Phase 2 trial for tobevibart, showing 100% virologic response in chronic hepatitis delta patients.
Why It Matters - Positive Phase 2 trial results for Vir Biotechnology's treatment could lead to significant market opportunities in chronic hepatitis delta, potentially boosting stock value and investor confidence.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology reported positive end-of-treatment results from its MARCH Phase 2 study on hepatitis B treatments, showing promising HBsAg loss in patients with low baseline levels.
Why It Matters - Promising clinical results for Vir Biotechnology's hepatitis B treatment could boost investor confidence, indicating potential market success and increased revenue opportunities.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
